Key result
Preoperative SGLT2 inhibitor therapy was associated with significantly reduced 1-year all-cause mortality following surgical aortic valve replacement.
Why the study?
Does preoperative SGLT2i therapy reduce 1-year all-cause mortality in patients undergoing surgical aortic valve replacement?
Does preoperative SGLT2i therapy reduce 1-year all-cause mortality in patients undergoing surgical aortic valve replacement?
Answers are grounded in this paper and cite their sources.
This letter emphasizes that studies evaluating SGLT2 inhibitors in surgical aortic valve replacement should account for diastolic dysfunction, metabolic syndrome, and baseline risk scores to accurately interpret mortality and morbidity outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Magoon et al. (2026) conducted a letter in Surgical aortic valve replacement. Sodium-glucose transport protein 2 inhibitor (SGLT2i) was evaluated on 1-year all-cause mortality. Preoperative SGLT2 inhibitor therapy was associated with significantly reduced 1-year all-cause mortality following surgical aortic valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: